نتائج البحث - Hsiaowei Deng

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    123I-<i>Meta</i>-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis

    123I-<i>Meta</i>-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis حسب Arnold Jacobson, Hsiaowei Deng, John Lombard, Harry J. Lessig, Richard R. Black

    منشور في 2010
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

    Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials حسب Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D. Barrett, Michele A. Weidner‐Wells, Hsiaowei Deng, David R. Matthews, Bruce Neal

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (<scp>CANVAS‐R</scp>): A randomized, placebo‐controlled trial

    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (<scp>CANVAS‐R</scp>): A randomized, placebo‐controlled trial حسب Bruce Neal, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Greg Fulcher, Gary Meininger, Ngozi Erondu, Mehul Desai, Wayne Shaw, Frank Vercruysse, Jacqueline Yee, Hsiaowei Deng, Dick de Zeeuw

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

    Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function حسب Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng, Norm Rosenthal, Meg Jardine, George L. Bakris, Vlado Perkovic

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

    A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMAN... حسب Mandeep R. Mehra, Muthiah Vaduganathan, Min Fu, João Pedro Ferreira, Stefan D. Anker, John G.F. Cleland, Carolyn S.P. Lam, Dirk J. van Veldhuisen, William M. Byra, Theodore E. Spiro, Hsiaowei Deng, Faı̈ez Zannad, Barry Greenberg

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial

    Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial حسب Jonathan W. Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D. Anker, William M. Byra, John G.F. Cleland, Mihai Gheorghiade, Carolyn S.P. Lam, David La Police, Mandeep R. Mehra, James D. Neaton, Theodore E. Spiro, Dirk J. van Veldhuisen, Barry Greenberg, Faı̈ez Zannad

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm

    Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm حسب Barry Greenberg, James D. Neaton, Stefan D. Anker, William M. Byra, John G.F. Cleland, Hsiaowei Deng, Min Fu, David A. La Police, Carolyn S.P. Lam, Mandeep R. Mehra, Christopher C. Nessel, Theodore E. Spiro, Dirk J. van Veldhuisen, Catherine M. Vanden Boom, Faı̈ez Zannad

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS)

    Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS) حسب C. Michael Gibson, Maria Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee, Shinya Goto, Jeffrey I. Weitz, Jay Horrow, Elliot S. Barnathan, Robert A. Harrington, Kenneth W. Mahaffey, Siniša Car, Karen S. Pieper, S. Claiborne Johnston, Graeme J. Hankey, Alexei N. Plotnikov, Danshi Li, Hsiaowei Deng, Philippe Gabríel Steg

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: